How are energy investors positioned?
In a recent transaction on August 23, Mario Guillermo Tabraue, the Chief Operating Officer (COO) of Earth Science Tech, Inc. (OTCMKTS:ETST), purchased shares of the company's common stock, signaling a vote of confidence in the pharmaceutical preparations firm. The transaction involved the acquisition of 6,000 shares at a price of $0.175 each, totaling an investment of $1,050.
The buy was executed on the open market, as noted in the mandatory disclosure filed with the Securities and Exchange Commission. Following this purchase, Tabraue's total holdings in Earth Science Tech stock have increased to 12,362,023 shares.
Investors often monitor insider transactions like these for insights into the perspectives of high-level executives on the company's current valuation and future prospects. Such transactions are publicly disclosed to ensure transparency and maintain fair trading practices in the market.
Earth Science Tech, based in Miami, Florida, operates in the pharmaceutical industry and is known for its specialization in pharmaceutical preparations. The company trades under the symbol ETST on the OTC Markets.
This latest acquisition by a key insider is a move that stakeholders in the company might find noteworthy as they assess Earth Science Tech's performance and outlook.
InvestingPro Insights
Earth Science Tech, Inc. (OTCMKTS:ETST) has been drawing attention not only through insider transactions but also through its remarkable financial metrics and stock performance. With a market capitalization of $60.24 million, the company has demonstrated a significant return over the last year, with a 280.77% price total return, reflecting investor confidence and a potentially bullish outlook for the stock.
An InvestingPro Tip highlights that Earth Science Tech has experienced a substantial price uptick over the last six months, boasting a 164.0% price total return during that period. This aligns with the recent insider purchase by COO Mario Guillermo Tabraue, possibly indicating an optimistic internal perspective on the company's value and future growth potential.
Furthermore, the company's financials underscore its high-growth narrative, with a staggering revenue growth of 7462.31% over the last twelve months as of Q1 2023. The gross profit margin stands at an impressive 69.4%, which may suggest efficient operations and strong pricing power within its niche in the pharmaceutical industry.
For those interested in diving deeper into Earth Science Tech's financial health and stock performance, there are additional InvestingPro Tips available, including insights on the company's earnings multiples and volatility. For instance, the company is trading at a high earnings multiple, with a P/E ratio of 24.23 and an adjusted P/E ratio for the last twelve months as of Q1 2023 at 31.63. This could indicate high expectations for future earnings growth, which investors should consider when evaluating the stock.
It's worth noting that Earth Science Tech does not pay a dividend to shareholders, which may be relevant for those investors seeking income through dividends. However, the strong price appreciation could be an attractive point for growth-focused investors.
For a more comprehensive analysis and additional InvestingPro Tips on Earth Science Tech, investors can visit the dedicated page at https://www.investing.com/pro/ETST.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.